Longevity / mitochondrial peptides
Mitochondria-derived and longevity-associated research peptides — among the most hype-prone and least clinically validated.
S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.
The category at a glance
Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.
Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.
CSS 31Moderate human evidenceLow overstatementResearch-use-only57/ 100
SS-31 (elamipretide) is a cardiolipin-targeting tetrapeptide that stabilizes the inner mitochondrial membrane — the most clinically advanced compound here, with real randomized trials in primary mitochondrial myopathy and Barth syndrome, and accelerated FDA approval for Barth syndrome. Strongest human evidence is in those specific mitochondrial diseases, not general anti-aging.
Tier read: moderate human evidence · low overstatement risk · low search interest · Early human. Why not D: supported by preclinical depth, mechanism confidence. Why not B: held back by regulatory clarity.
Read the full SS 31 profile →FMots CEarly human evidenceMedium overstatementResearch-use-only30/ 100
A mitochondrial-derived peptide studied for metabolism and exercise biology — predominantly preclinical (cell and animal models). No approved therapeutic use and essentially no human outcome trials; among the more hype-prone longevity peptides.
Tier read: early human evidence · medium overstatement risk · low search interest · Animal. Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full Mots C profile →FHumaninEarly human evidenceMedium overstatementResearch-use-only28/ 100
A mitochondrial-derived peptide first identified for protecting neurons against amyloid-β toxicity, with cytoprotective activity across metabolic and neurodegenerative models. Evidence is predominantly preclinical and biomarker/observational in humans; no approved therapies or pivotal trials.
Tier read: early human evidence · medium overstatement risk · low search interest · Animal. Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full Humanin profile →FEpitalonEarly human evidenceMedium overstatementResearch-use-only22/ 100
A synthetic tetrapeptide (“bioregulator”) promoted for longevity. Human data is mostly older, small, single-group (Russian) studies that have not been independently replicated at scale; it is unapproved and clinically unvalidated. High hype, weak evidence.
Tier read: early human evidence · medium overstatement risk · low search interest · Anecdote. Why not D: held back by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
Read the full Epitalon profile →FFoxo4 DRIWeak human evidenceHigh overstatementResearch-use-only15/ 100
A synthetic D-retro-inverso senolytic peptide that disrupts the FOXO4–p53 interaction to trigger apoptosis in senescent cells. In the landmark Baar study it improved healthspan markers in aged and progeroid mice. Evidence is entirely preclinical — no human trials.
Tier read: weak human evidence · high overstatement risk · low search interest · Mechanism. Why not D: held back by human evidence, preclinical depth, safety clarity, regulatory clarity, practical relevance.
Read the full Foxo4 DRI profile →FPinealonWeak human evidenceHigh overstatementResearch-use-only12/ 100
A synthetic tripeptide (Glu-Asp-Arg / EDR), one of the Russian “peptide bioregulators” proposed to modulate neuroprotective gene expression. Reported effects derive almost entirely from preclinical work and small Russian-language studies; rigorous, independently replicated human trials are lacking.
Tier read: weak human evidence · high overstatement risk · low search interest · Anecdote. Why not D: held back by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
Read the full Pinealon profile →Longevity and mitochondrial peptides are the most hype-prone, least clinically validated category here. The science is genuinely interesting at the cell level; the human lifespan claims are speculative.
Start with the best-supported options: SS 31. Then compare them before exploring research-only compounds.
No broad human winner yet for this goal — the strongest evidence is still limited.
What the evidence actually supports
Mitochondria-targeting and mitochondrial-derived peptides (SS-31/elamipretide, MOTS-c, humanin) have plausible mechanisms and, for SS-31, human clinical trials in mitochondrial/cardiac disease. Most longevity peptides (epitalon, pinealon, FOXO4-DRI) rest on limited, older, or animal-only work.
Where the hype outruns the data
Human lifespan extension, telomere lengthening in people, and “reversing aging” are not established. Several popular compounds trace to a single research group or to mouse studies. This is the category to read most skeptically.
FAQ
Do longevity peptides extend human lifespan?
No — human lifespan-extension and telomere claims are speculative and unproven. The mechanisms are interesting; the human outcomes aren't there.
Which is the most clinically advanced?
SS-31 (elamipretide) has reached human trials, though results have been mixed. Most others are preclinical.
Is this medical advice?
No — research reference only.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.